Does losartan (Cozaar) slow the progression of renal disease in patients with type 2 diabetes and nephropathy?
Pierce, H.L.; Stevermer, J.J.
Journal of Family Practice 50(12): 1083
2001
ISSN/ISBN: 0094-3509 PMID: 11742614 Document Number: 527183
Document emailed within 1 workday
Related Documents
Burgess, E.D.; Carides, G.W.; Gerth, W.C.; Marentette, M.A.; Chabot, I. 2004: Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective Canadian Journal of Cardiology 20(6): 613-618Majdan, M.; Kurowska, M.; Orłowska-Kowalik, G.; Drop, A. 2005: Ultrasonographic evaluation of kidneys in type-2 diabetes patients without overt nephropathy and with chronic renal failure Wiadomosci Lekarskie 58(1-2): 25-28
Lindner, T. 2008: Aliskiren combined with losartan in diabetes and nephropathy New England Journal of Medicine 359(10): 1068-1069; Author Reply 1069-1070
Zerbini, G.; Gabellini, D.; Maestroni, S.; Maestroni, A. 2007: Early renal dysfunctions in type 1 diabetes and pathogenesis of diabetic nephropathy Journal of Nephrology 20(Suppl): S19-S22
Vesti-Nielsen, J.ør.; Westerlund, P.; Bygren, P. 2008: Low carbohydrate diet slowed down the progression of renal insufficiency in type 2 diabetes. a case--difficult to draw conclusions Lakartidningen 105(30-31): 2094-2097
Galicka-Latała, D.; Fedak, D.; Kuźniewski, M.; Kawalec, E.; Solnica, B. 2004: Cardiovascular autonomic neuropathy and nephropathy in patients with type-1 diabetes mellitus Przeglad Lekarski 61(3): 155-158
Rossert, J.; Ronco, P. 2001: How to slow the progression of chronic renal insufficiency La Revue du Praticien 51(4): 378-384
González, E.; Ortiz, M.; Praga, M. 2001: Diabetes and kidneys: predictors of nephropathy and progression factors Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 21(Suppl 3): 46-51
Onuchin, S.G.; Elsukova, O.S.; Solov'ev, O.V.; Onuchina, E.L. 2010: Cardiovascular disorders and possibilities of their therapy in patients with type 2 diabetes mellitus and diabetic nephropathy Klinicheskaia Meditsina 88(1): 32-37
Krairittichai, U.; Potisat, S.; Jongsareejit, A.; Sattaputh, C. 2011: Prevalence and risk factors of diabetic nephropathy among Thai patients with type 2 diabetes mellitus Journal of the Medical Association of Thailand 94(Suppl 2): S1-S5
Nelaeva, A.A.; Khasanova, I.V.; Khobotova, E.S. 2013: Role of proinflammatory cytokines in the development and progression of micro- and macroangiopathies in patients with type 2 diabetes mellitus Angiologiia i Sosudistaia Khirurgiia 19(3): 9-13
Singh, A.; Kalita, B.Chandra. 2020: A Study of Association of XBAI GLUT1 Gene Polymorphism in Patients of Type 2 Diabetes Mellitus with Diabetic Nephropathy Journal of the Association of Physicians of India 68(1): 50
Krairittichai, U.; Chaisuvannarat, V. 2009: Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy Journal of the Medical Association of Thailand 92(5): 611-617
Kazakova, I.A.; Trusov, V.V.; Cheremiskina, I.B. 2003: Clinical significance of assessment of the metabolism of connective-tissue biopolymers in patients with type 1 diabetes mellitus and with diabetic nephropathy Klinicheskaia Laboratornaia Diagnostika 10: 19-22
Hosojima, H. 2002: Intrarenal resistive index (RI) from renal duplex Doppler sonography in type Ii diabetic patients with nephropathy Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 8): 676-681
Winkler, K.; Abletshauser, C.; Hoffmann, M.M.; Friedrich, I.; Baumstark, M.W.; Wieland, H.; März, W. 2002: Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action Journal of Clinical Endocrinology and Metabolism 87(12): 5485-5490
Bulum, T.; Prkacin, I.; Blaslov, K.; Zibar, K.; Duvnjak, L. 2013: Association between red blood cell count and renal function exist in type 1 diabetic patients in the absence of nephropathy Collegium Antropologicum 37(3): 777-782
Zidek, W. 2004: Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2 MMW Fortschritte der Medizin 146(42): 51-52
Polena, S.; Yang, S.; Alam, R.; Gricius, J.; Gupta, J.R.; Badalova, N.; Chuang, P.; Gintautas, J.; Conetta, R. 2005: Nephropathy in critically Ill patients without preexisting renal disease Proceedings of the Western Pharmacology Society 48: 134-135
Remuzzi, G. 2000: Renal protection: progression, regression, remission from nephropathy beyond blood pressure control International Journal of Clinical Practice. Supplement 2000(110): 9-15